The pharmaceutical executive who gained notoriety for drastically raising the price of a widely-used drug by more than 5000 percent is also an e-sports team owner.

Turing Pharmaceuticals CEO Martin Shkreli drew widespread criticism this week for increasing the price of Daraprim, a drug used to treat cancer patients and people with AIDS and HIV, from US$13.50 a pill to US$750.

The former hedge fund manager acquired the rights to the drug, which is used to treat toxoplasmosis, last month.

He claimed the price hike was necessary, as Turing wants to further research treatments for the illness, but the idea that the 62-year-old drug was unsuitable has been rejected by patients.

Now it has come to light that Shkreli is the owner of League of Legends team Imagine and North American Dota 2 team Leviathan.

When Shkreli entered the MOBA scene earlier this year, his legitimacy was questioned by The Daily Dot’s Jacob Wolf, who wrote that Shkreli was “dogged by allegations of misconduct” from his previous stint as the CEO of pharmaceutical company Retrophin.

According to Bloomberg, "Shkreli's shenanigans involved payouts of millions of dollars and the transfer of hundreds of thousands of shares of Retrophin stock," behavior that "sparked a wave of civil lawsuits against Retrophin and Shkreli." The company also revealed that Shkreli was under criminal investigation by the U.S. Attorney's office for New York's Eastern District.

Retrophin is currently suing Shkreli for US$65 million.